Literature DB >> 17552366

Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer.

Gaynor Davies1, Richard J Ablin, Malcolm D Mason, Wen G Jiang.   

Abstract

BACKGROUND: Prostate transglutaminase (TGase-4), has been identified as a TGase that has a pattern of prostate specific expression. This study sought to determine (i) the level of TGase-4 in human cancer cell lines including prostate cancer cells; (ii) to investigate the effect after knocking down the expression of TGase-4 transcript using a ribozyme transgene; (iii) to establish the effect of HGF/SF, a pro-invasion/metastasis cytokine, on the invasive capacity of TGase-4 knockdown cells.
METHODS: RT-PCR and quantitative RT-PCR were used to assess the presence of TGase-4 transcript at the mRNA level in a panel of 26 cell lines including 6 prostate cancer cell lines (PC-3, DU-145, CA-HPV-10, PZ-HPV-7, PNT2C2 and PNT1A). A ribozyme transgene consisting of hammerhead ribozyme and antisense specific to TGase-4 was constructed using a pEF6 expression vector and transfected into CA-HPV-10 cell, a cell line highly expressed TGase-4. An in vitro invasion assay assessed the effects of HGF/SF on cell invasiveness.
RESULTS: TGase-4 transcript was detected in a number of cell lines, including prostate, colorectal, lung and breast tumour cells. At the mRNA level, TGase-4 was strongly expressed in CA-HPV-10 cells with lower levels of expression seen in PC-3, DU-145, PZ-HPV-7 and PNT1A cells. TGase-4 knock-down in CA-HPV-10 cells was established at the mRNA level. HGF/SF significantly increased the invasion of wild type (21.67 +/- 0.88; P < 0.001 vs. control 8.67 +/- 0.67) and control plasmid transfected cells (16.33 +/- 0.88; P < 0.001 vs. control 7.67 +/- 0.88) compared with untreated cells. However, cells transfected with the TGase-4 ribozyme transgene had a reduced invasive capacity (9.33 +/- 0.88 P < 0.01 vs. control 4.33 +/- 0.88) through Matrigel.
CONCLUSION: TGase-4 has a relatively wide profile of expression in human cancer cell lines and is strongly expressed in the low invasive CA-HPV-10 prostate cancer cell line. The molecule is associated with the invasive potential of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552366

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  10 in total

1.  The role of transglutaminases in the pathophysiology of prostate cancer.

Authors:  R J Ablin; W G Jiang
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling.

Authors:  S Deasey; D Nurminsky; S Shanmugasundaram; F Lima; M Nurminskaya
Journal:  Cell Signal       Date:  2013-08-29       Impact factor: 4.315

3.  Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.

Authors:  Sung-Yup Cho; Kyungho Choi; Ju-Hong Jeon; Chai-Wan Kim; Dong-Myung Shin; Jong Bouk Lee; Sang Eun Lee; Choung-Soo Kim; Jeong-Soo Park; Eui Man Jeong; Gi-Yong Jang; Kye-Yong Song; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

4.  Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.

Authors:  Andrei P Drabovich; Punit Saraon; Mikalai Drabovich; Theano D Karakosta; Apostolos Dimitromanolakis; M Eric Hyndman; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2019-06-27       Impact factor: 5.911

5.  Changes in proteomic profiles in different prostate lobes of male rats throughout growth and development and aging stages of the life span.

Authors:  Arunangshu Das; James D Bortner; Cesar A Aliaga; Aaron Baker; Anne Stanley; Bruce A Stanley; Matthew Kaag; John P Richie; Karam El-Bayoumy
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

6.  Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.

Authors:  Zhi Cao; Yang Wang; Zhi-Yong Liu; Zhen-Sheng Zhang; Shan-Cheng Ren; Yong-Wei Yu; Meng Qiao; Bei-Bei Zhai; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

7.  Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer.

Authors:  Richard J Ablin; Howard G Kynaston; Malcolm D Mason; Wen G Jiang
Journal:  J Transl Med       Date:  2011-04-28       Impact factor: 5.531

8.  Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance.

Authors:  Guillermo C Rivera-Gonzalez; Alastair P Droop; Helen J Rippon; Katrin Tiemann; Davide Pellacani; Lindsay J Georgopoulos; Norman J Maitland
Journal:  Nucleic Acids Res       Date:  2012-02-22       Impact factor: 16.971

9.  Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Authors:  Wen G Jiang; Lin Ye; Andrew J Sanders; Fiona Ruge; Howard G Kynaston; Richard J Ablin; Malcolm D Mason
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

10.  Biochemical Characterisation of Human Transglutaminase 4.

Authors:  Zsuzsa Csobán-Szabó; Bálint Bécsi; Saïd El Alaoui; László Fésüs; Ilma Rita Korponay-Szabó; Róbert Király
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.